scholarly journals Evaluation of Cytomegalovirus (CMV)–Specific T Cell Immune Reconstitution Revealed That Baseline Antiviral Immunity, Prophylaxis, or Preemptive Therapy but not Antithymocyte Globulin Treatment Contribute to CMV‐Specific T Cell Reconstitution in Kidney Transplant Recipients

2010 ◽  
Vol 202 (4) ◽  
pp. 585-594 ◽  
Author(s):  
Davide Abate ◽  
Alda Saldan ◽  
Marta Fiscon ◽  
Simona Cofano ◽  
Adriana Paciolla ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
Antithymocyte Globulin ◽  
Immune Reconstitution ◽  
Antiviral Immunity ◽  
Preemptive Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
T Cell Reconstitution

Impact of Anti–T-Cell Therapy in the Immunogenicity of Seasonal Influenza Vaccine in Kidney Transplant Recipients

2012 ◽  
Vol 94 (6) ◽  
pp. 630-636 ◽  
Author(s):  
Angela Orcurto ◽  
Manuel Pascual ◽  
Katja Hoschler ◽  
Vincent Aubert ◽  
Pascal Meylan ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Influenza Vaccine ◽  
Kidney Transplant ◽  
Seasonal Influenza ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
T Cell Therapy ◽  
Seasonal Influenza Vaccine

scholarly journals CD4+T cell levels are decreased during active CMV infection in kidney transplant recipients

2002 ◽  
Vol 34 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Sahar Essa ◽  
Alexander S Pacsa ◽  
Raj Raghupathy ◽  
Raja'a Al-Attiyah ◽  
Amany El-Shazly ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
Cd4 T Cell ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cmv Infection

scholarly journals Infection-Related Mortality in Recipients of a Kidney Transplant in Australia and New Zealand

2019 ◽  
Vol 14 (10) ◽  
pp. 1484-1492 ◽  
Author(s):  
Samuel Chan ◽  
Elaine M. Pascoe ◽  
Philip A. Clayton ◽  
Stephen P. McDonald ◽  
Wai H. Lim ◽  
...  
Keyword(s):  
New Zealand ◽  
T Cell ◽  
General Population ◽  
Kidney Transplant ◽  
Older Age ◽  
Competing Risk ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Female Sex ◽  
Related Mortality

Background and objectivesThe burden of infectious disease is high among kidney transplant recipients because of concomitant immunosuppression. In this study the incidence of infectious-related mortality and associated factors were evaluated.Design, setting, participants, & measurementsIn this registry-based retrospective, longitudinal cohort study, recipients of a first kidney transplant in Australia and New Zealand between 1997 and 2015 were included. Cumulative incidence of infectious-related mortality was estimated using competing risk regression (using noninfectious mortality as a competing risk event), and compared with age-matched, populated-based data using standardized incidence ratios.ResultsAmong 12,519 patients, (median age 46 years, 63% men, 15% diabetic, 6% Indigenous ethnicity), 2197 (18%) died, of whom 416 (19%) died from infection. The incidence of infection-related mortality during the study period (1997–2015) was 45.8 (95% confidence interval [95% CI], 41.6 to 50.4) per 10,000 patient-years. The incidence of infection-related mortality reduced from 53.1 (95% CI, 45.0 to 62.5) per 10,000 person-years in 1997–2000 to 43.9 (95% CI, 32.5 to 59.1) per 10,000 person-years in 2011–2015 (P<0.001) Compared with the age-matched general population, kidney transplant recipients had a markedly higher risk of infectious-related death (standardized incidence ratio, 7.8; 95% CI, 7.1 to 8.6). Infectious mortality was associated with older age (≥60 years adjusted subdistribution hazard ratio [SHR], 4.16; 95% CI, 2.15 to 8.05; reference 20–30 years), female sex (SHR, 1.62; 95% CI, 1.19 to 2.29), Indigenous ethnicity (SHR, 2.87; 95% CI, 1.84 to 4.46; reference white), earlier transplant era (2011–2015: SHR, 0.39; 95% CI, 0.20 to 0.76; reference 1997–2000), and use of T cell–depleting therapy (SHR, 2.43; 95% CI, 1.36 to 4.33). Live donor transplantation was associated with lower risk of infection-related mortality (SHR, 0.53; 95% CI, 0.37 to 0.76).ConclusionsInfection-related mortality in kidney transplant recipients is significantly higher than the general population, but has reduced over time. Risk factors include older age, female sex, Indigenous ethnicity, T cell–depleting therapy, and deceased donor transplantation.PodcastThis article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_08_27_CJN03200319.mp3

Sign in / Sign up

Export Citation Format

Share Document